Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
about
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasThe casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.BIRC6 mediates imatinib resistance independently of Mcl-1.Casein kinase: the triple meaning of a misnomer.Casein kinases as potential therapeutic targets.Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant MelanomaBCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.CK2 modulates adipocyte insulin-signaling and is up-regulated in human obesity.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Q26769590-18CF0F68-E887-4AC1-A786-4C73B6DDDC5FQ34471660-7DE187DF-6BF1-4E26-AAA2-40DA0155868EQ36143247-CA2310D8-59BF-4AC5-8CA7-5CD3A251C980Q36375641-4ECDF1FC-D9DF-42DC-A2FE-9647D6E21620Q38211598-0E2C280F-AB6C-43CB-96A1-7C008AA58B8CQ38632634-D2DFDB71-68B0-4115-B6E4-9DD39BBB6ACFQ38768362-84BCAA5B-8FBF-4805-AF0B-18AA21D943D0Q41813901-4D343C6B-85A8-4266-A3EC-7EDC2F93B0B8Q42412981-DD8695AB-5C9C-4562-A6EE-A1D530D223F2Q46085978-CC49A90E-749C-49D0-A812-3B56E6EC142DQ47133076-0122961E-27D1-4555-9B4C-EFD465951818Q47677919-40BBBDFE-16F0-4FD1-B91F-C567CDD4262B
P2860
Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Aberrant signalling by protein ...... and therapeutic perspectives.
@en
type
label
Aberrant signalling by protein ...... and therapeutic perspectives.
@en
prefLabel
Aberrant signalling by protein ...... and therapeutic perspectives.
@en
P2093
P2860
P50
P1433
P1476
Aberrant signalling by protein ...... and therapeutic perspectives.
@en
P2093
Arianna Donella-Deana
Luca Cesaro
Maria Lina Massimino
Valentina Salizzato
P2860
P304
P356
10.1016/J.MOLONC.2013.08.006
P577
2013-08-22T00:00:00Z